 |
|
A Comparison of the Effect of Ipratropium and Albuterol in the Treatment of Chronic Obstructive Airway Disease
Sheldon R. Braun, MD;
Wayland N. McKenzie, PhD;
Cheryl Copeland, RN;
Lester Knight, RCPT;
Mark Ellersieck, PhD
Arch Intern Med. 1989;149(3):544-547.
Abstract
• Twenty-five subjects with moderate to severe chronic obstructive airway disease were studied to compare the effect of ipratropium bromide, albuterol, and placebo on the forced expiratory volume in 1 s, (FEV1), forced vital capacity, heart rate, and blood pressure during six hours. Ipratropium produced a significantly greater improvement than albuterol in the FEV1 at 30 minutes and at 3, 4, and 5 hours and in the forced vital capacity at one through six hours. Fifteen subjects did not demonstrate a 15% improvement and at least a 200-mL increase in the FEV1 15 minutes after metaproterenol sulfate aerosol. All 15 did improve after ipratropium therapy during the study. Ipratropium was effective significantly longer than albuterol. Subjects with better peak responses to ipratropium had a lower FEV1 percent predicted and a greater pack-year smoking history. In patients with chronic obstructive airway disease, ipratropium produces a longer duration of action than albuterol. It is more effective than albuterol in treating severely obstructed individuals and those not responding to metaproterenol. It is equally effective in treating others.
(Arch Intern Med 1989;149:544-547)
Author Affiliations
From the Department of Medicine, Division of Pulmonary, Critical Care, and Environmental Medicine, University of Missouri School of Medicine (Drs Braun and McKenzie and Ms Copeland), the Department of Medicine, Harry S Truman Veterans Administration Hospital (Mr Knight), and the Agricultural Experimental Station (Dr Ellersieck), Columbia, Mo.
Footnotes
Accepted for publication Oct 26, 1988.
Reprint requests to Room MA419, Health Sciences Center, One Hospital Dr, Columbia, MO 65212 (Dr Braun).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Bronchodilator treatment of stable COPD: long-acting anticholinergics
Vincken
Eur Respir Rev 2005;14:23-31.
ABSTRACT
| FULL TEXT
Chronic obstructive pulmonary disease: the clinical management of an acute exacerbation
Hurst and Wedzicha
Postgrad. Med. J. 2004;80:497-505.
ABSTRACT
| FULL TEXT
Inhaled Formoterol Dry Powder Versus Ipratropium Bromide in Chronic Obstructive Pulmonary Disease
DAHL et al.
Am. J. Respir. Crit. Care Med. 2001;164:778-784.
ABSTRACT
| FULL TEXT
Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD
Ayers et al.
Eur Respir J 2001;17:1132-1137.
ABSTRACT
| FULL TEXT
Pharmacoeconomic Evaluation of COPD
Hilleman et al.
Chest 2000;118:1278-1285.
ABSTRACT
| FULL TEXT
The Effects of Oxitropium Bromide on Exercise Performance in Patients with Stable Chronic Obstructive Pulmonary Disease . A Comparison of Three Different Exercise Tests
OGA et al.
Am. J. Respir. Crit. Care Med. 2000;161:1897-1901.
ABSTRACT
| FULL TEXT
Apples and Oranges : Flaws and Guffaws
Petty et al.
Chest 1999;116:1137-1138.
FULL TEXT
Clinical evidence: Stable chronic obstructive pulmonary disease
Kerstjens
BMJ 1999;319:495-500.
FULL TEXT
Effects of Inhaled Bronchodilators on Pulmonary Hemodynamics at Rest and During Exercise in Patients With COPD
Saito et al.
Chest 1999;115:376-382.
ABSTRACT
| FULL TEXT
Building a National Strategy for the Prevention and Management of and Research in Chronic Obstructive Pulmonary Disease: National Heart, Lung, and Blood Institute Workshop Summary
Petty and Weinmann
JAMA 1997;277:246-253.
ABSTRACT
The Pharmacological Treatment of Ambulatory Chronic Obstructive Pulmonary Disease Patients
DeYoung et al.
Journal of Pharmacy Practice 1992;5:204-216.
ABSTRACT
Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Rexing et al.
Journal of Pharmacy Practice 1992;5:217-223.
ABSTRACT
|
